Literature DB >> 34819662

Novel de novo pathogenic variant in the GNAI1 gene as a cause of severe disorders of intellectual development.

Marketa Wayhelova1,2,3, Vladimira Vallova4,5, Petr Broz4,6, Aneta Mikulasova7, Dominika Loubalova4, Hana Filkova5, Jan Smetana4, Klara Drabova8, Renata Gaillyova8, Petr Kuglik9,10.   

Abstract

Pathogenic sequence variant in the GNAI1 gene were recently introduced as a cause of novel syndrome with a manifestation of variable developmental delay and autistic features. In our study, we report a case of monozygotic twins with severe intellectual disability and motor delay and developmental dysphasia. Both probands and their parents were examined using multi-step molecular diagnostic algorithm including whole-exome sequencing (WES), resulting in the identification of a novel, de novo pathogenic sequence variant in the GNAI1 gene, NM_002069.6:c.815 A>G, p.(Asp272Gly) in probands. Using WES we also verified the microarray findings of a familial 8q24.23q24.3 duplication and heterozygous 5q13.2 deletion, not associated with clinical symptoms in probands. Our results confirmed the role of the GNAI1 gene in the pathogenesis of syndromic neurodevelopmental disorders. They support trio- or quatro-based WES as a suitable molecular diagnostics method for the simultaneous detection of clinically relevant sequence variants and CNVs in individuals with neurodevelopmental disorders and rare diseases.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.

Entities:  

Mesh:

Year:  2021        PMID: 34819662     DOI: 10.1038/s10038-021-00988-w

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  1 in total

1.  Novel de novo frameshift variant in the ASXL3 gene in a child with microcephaly and global developmental delay.

Authors:  Marketa Wayhelova; Jan Oppelt; Jan Smetana; Eva Hladilkova; Hana Filkova; Eva Makaturova; Petra Nikolova; Rastislav Beharka; Renata Gaillyova; Petr Kuglik
Journal:  Mol Med Rep       Date:  2019-05-27       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.